Device Trial Radar · NCT05152524
Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
149
Actual
Start
Mar 25, 2022
Primary completion
Dec 30, 2025
Study completion Mar 30, 2026
Sponsor
- Lead sponsor
- Rapid MedicalNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 10, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO), as compared to medical management.
Conditions
- Ischemic Stroke
- Neovascularization
Interventions
Tigertriever 13Device
patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO) will be treated with the Tigertriever 13 device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Successful reperfusion (CTP or MR PWI*) without sICH**.Time frame: 24±6 Hours post randomization
Locations
20 sites in 4 countries. Site status is shown where the registry gives one.
Lakewood Regional Medical Center
Los Angeles, California
19 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.